SCHEMBL7782582

SCHEMBL7782582

CCCCCn1c(C)c(C(=O)c2ccc(Br)c3ccccc23)c2cccc(OC)c21

nearest known ligand 0.71

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 19/20 0.71
CNR1 P21554 9/20 0.71
SLC6A3 Q01959 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7777725 0.88 CNR2 (0.71) CNR2CNR1SLC6A3
SCHEMBL7782586 0.86 CNR2 (0.74) CNR2CNR1SLC6A3
SCHEMBL8060941 0.83 CNR2 (1.00) CNR2CNR1
SCHEMBL29388664 0.79 CNR2 (1.00) CNR2CNR1SLC6A3
SCHEMBL29988815 0.72 CNR2 (1.00) CNR2CNR1SLC6A3
SCHEMBL6331573 0.72 CNR2 (1.00) CNR2CNR1SLC6A3
SCHEMBL29388381 0.72 CNR2 (1.00) CNR2CNR1SLC6A3
SCHEMBL8071354 0.72 CNR2 (0.80) CNR2CNR1
SCHEMBL8061024 0.72 CNR2 (0.80) CNR2CNR1
SCHEMBL29988425 0.71 CNR2 (1.00) CNR2CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0833818-B1 3-ACYLINDOLES AS CB2 RECEPTOR AGONISTS SANOFI SYNTHELABO (FR) 2001-10-17 EP claimed
EP-0833818-A1 CB 2? RECEPTOR AGONIST COMPOUNDS SANOFI (FR) 1998-04-08 EP claimed
WO-1997000860-A1 CB2 RECEPTOR AGONIST COMPOUNDS SANOFI (FR) 1997-01-09 WO claimed
US-20170240521-A1 PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-08-24 US disclosed
US-9656981-B2 Peripherally-acting cannabinoid receptor agonists for chronic pain THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2017-05-23 US disclosed
US-20150239859-A1 PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2015-08-27 US disclosed
EP-0833818-B1 3-ACYLINDOLES AS CB2 RECEPTOR AGONISTS SANOFI SYNTHELABO (FR) 2001-10-17 EP disclosed
US-6013648-A IMMUNOMODULATORS SANOFI (FR) 2000-01-11 US disclosed
EP-0833818-A1 CB 2? RECEPTOR AGONIST COMPOUNDS SANOFI (FR) 1998-04-08 EP disclosed
WO-1997000860-A1 CB2 RECEPTOR AGONIST COMPOUNDS SANOFI (FR) 1997-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150239859-A1 PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN CNR2, CNR1, OPRL1 CNR2 1/4885CNR1 2/4885SLC6A3 999/4885
US-20170240521-A1 PERIPHERALLY-ACTING CANNABINOID RECEPTOR AGONISTS FOR CHRONIC PAIN CNR2, CNR1, OPRL1 CNR2 1/4885CNR1 2/4885SLC6A3 999/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.